Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
  • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
  • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

• the present invention concerns a process for the preparation of pyrimidines and intermediate compounds useful in the preparation thereof.
• Substituted pyrimidine compounds are valuable compounds for use in particularly the pharmaceutical industry.
• Certain 2-aminopyrimidine compounds are intermediates used in the preparation of pharmaceutical compounds useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and artherosclerosis.
• Synthetic routes to substituted pyrimidine compounds have been disclosed in EP-A-0 521 471 and WO01/04100. Nevertheless, it remains desirable to identify alternative routes for the preparation of substituted pyrimidine compounds.
• R 1 is H or an alkyl group
• R 2 is H or an alkyl or aryl group
• R 3 and R 4 are each independently H, alkyl or aryl, or R 3 and R 4 are linked to form, together with the nitrogen to which they are attached, a 5 to 7 membered heterocyclic ring;
• Dihydropyrimidines formed in step a) can be represented by the Formula (2):
• the compounds of Formula (2) can exist in a number of tautomeric forms in which the double bonds are delocalised into other positions in the molecule, notably into different positions around the pyrimidine ring. Without wishing to be bound by any theory, it is believed that for certain compounds of Formula 2, the predominant tautomeric form is of Formula (2a):
• Alkyl groups which may be represented by R 1 include linear, branched and cyclic alkyl groups commonly comprising from 1 to 8 carbon atoms.
• Preferred cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
• Preferred linear and branched alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl and tert-butyl groups. Most preferably, R 1 represents isopropyl.
• Alkyl groups which may be represented by R 2 are as described above for R 1 .
• Aryl groups which may be represented by R 2 include both homoaryl and heteroaryl groups, and commonly comprise at least one 5 to 7 membered aromatic ring. Examples of aryl groups include phenyl, naphthyl and pyridyl groups. Most preferably, R 2 represents a phenyl group.
• R 3 and R 4 Alkyl and aryl groups which may be represented by R 3 and R 4 are as described above for R 1 and R 2 .
• R 3 represents methyl and R 4 represents H.
• both of R 3 and R 4 are H.
• Alkyl and aryl groups which may be represented by R 1 , R 2 , R 3 and R 4 may be unsubstituted or substituted by one or more substituents.
• substituents include optionally substituted alkoxy (preferably C ⁇ -alkoxy), optionally substituted alkyl (preferably C ⁇ -alkyl), optionally substituted aryl (preferably phenyl), optionally substituted aryloxy (preferably phenoxy), optionally substituted heterocyclyl, polyalkylene oxide (preferably polyethylene oxide or polypropylene oxide), carboxy, oxo, phosphato, sulpho, nitro, cyano, halo, especially chloro and fluoro, ureido, -SO 2 F, hydroxy, ester, -NR a R b , -COR a , -CONR a R b , -NHCOR a , carboxyester, sulphone, and -SO 2 NR a R b wherein R
• Unsubstituted alkyl groups which may be represented by E are those unsubstituted alkyl groups as described above for R 1 .
• Aryl groups which may be represented by E are as described above for R 2 .
• Electron withdrawing groups which may be represented by E include nitro groups; nitrile groups; perhaloalkyl groups, such as trifluoromethyl and pentafluoroethyl; ester groups, especially alkyl carboxylate groups; sulphonamide groups; keto groups; amide groups; and aldehyde groups, especially formyl groups.
• E may also represent a group of formula -CHX a X b , wherein X a and X b each independently represents a halo, especially a chloro or bromo group, an alkoxy group, especially a C- ⁇ alkoxy, such as a methoxy or ethoxy group, an alkylthio group, especially a C ⁇ alkylthio group, or X a and X b are linked to form a cyclic acetal or thioacetal commonly comprising, with the carbon to which X a and X are bonded, from 5 to 7 atoms in the ring.
• E represents a group of formula -CHX a X b
• it is preferred that X a is the same as X b .
• R c represents an alkyl, such as a C ⁇ alkyl, or an aryl, such as a
• R* and R y represent H
• R z represents an optionally substituted C 1 -5 alkyl chain.
• R 2 is preferably substituted by two hydroxy groups, commonly present as a protected 1 ,3-dihydroxy moiety.
• R z preferably comprises a terminal carboxyl group, especially a carboxy ester group.
• R z is most preferably a group of formula:
• R* is an alkyl group, preferably a tert-butyl group.
• R 1 -CO-CH 2 -E is of formula:
• R' is an alkyl group, preferably a tert-butyl group.
• E represents a group of formula -CO 2 (C 1 - alkyl), and especially -CO 2 Me, -CO 2 Et or -CO 2 iPr.
• Oxidising agents which may be employed in the process according to the present invention include those oxidising agents known in the art to oxidise dihydropyrimidines to pyrimidines.
• suitable oxidising agents include quinones, such as chloranil, and particularly substituted benzoquinones such as 2,3-dichloro-5,6-dicyano-1 ,4- benzoquinone; halogens, such as bromine, transition metal oxidants such as barium manganate, copper chloride, optionally in the presence of phenanthroline, and manganese dioxide; metallic oxidants, such as palladium on charcoal or other suitable platinum group metals; and elemental sulfur.
• the most preferred oxidants are elemental sulfur and manganese dioxide.
• the product of the reaction obtained from step (a) is the substituted pyrimidine rather than a dihydropyrimidine.
• any dihydropyrimidine formed is autoxidised to the pyrimidine by the presence of oxygen, or the dihydropyrimidine self-oxidises or disproportionates.
• Preferred compounds of formula R 1 -CO-CH 2 -E are compounds of formula (C ⁇ alkyl)-CO-CH 2 CO 2 R 5 , wherein R 5 represents a C ⁇ alkyl group, especially a methyl, ethyl or isopropyl group.
• Most preferred compounds of formula R 1 -CO-CH 2 -E are compounds of formulae: C-CH,C0 2 CH 3 — C-CH 2 C0 2 C,H 5 and )— C-CH 2 C-0
• Preferred compounds of formula R 2 -CHX 1 X 2 are compounds of formula:
• X 3 represents a substituent, especially halo, and n is 0 or 1-5.
• X 3 is chloro or fluoro, alkyl, preferably methyl, or alkoxy, preferably methoxy.
• n is 1 , and X 3 is present at the 4-position.
• 4-fluorobenzaldehyde is especially preferred.
• Bases which can be employed in the process of the present invention are preferably inorganic bases.
• inorganic bases include alkali and alkaline earth metal carbonates and hydrogencarbonates, particularly sodium or potassium hydrogencarbonate and most preferably sodium or potassium carbonate.
• Step a) of the process according to the present invention preferably employs a solvent which is inert under the reaction conditions employed.
• a polar solvent is employed, preferably a polar aprotic solvent, for example including dichloromethane, dimethylsulphoxide and tetrahydrofuran.
• Preferred solvents are amides, such as N-methylpyrrolidinone and especially dimethylformamide and dimethylacetamide. Mixtures of solvents may be employed if desired.
• Step a) of the present invention the process may be varied over a wide range, depending for example on the nature of the reagents and/or solvent employed.
• Step a) commonly employs a reaction temperature in the range of from about 50°C to about 80°C, such as from about 55° to 65°C.
• a stoichiometric mole ratio, or a small molar excess, such as up to about 1.2 : 1 , of compound of formula R 2 -CHX 1 X 2 to compound of formula R 1 -CO-CH 2 -E is employed.
• Step b) of the process preferably employs a solvent which is inert under the reaction conditions employed.
• the solvent is selected according to the nature of the oxidising agent employed, and may include the solvents described above for step a).
• Further solvents which may be employed in step b) include non-polar solvents, for example hydrocarbons, such as toluene, and dialkylethers, such as methyl tertiary-butyl ether. Mixtures of solvents may be employed if desired.
• Step b) of the process according to the present invention may be varied over a wide range, depending for example on the nature of the oxidant and/or solvent employed.
• Step b) commonly employs a reaction temperature in the range of from about 50°C to about 140°C, such as from about 100°C to 120°C.
• a stoichiometric mole ratio, or a molar excess of oxidant to dihydropyrimidine is employed.
• the oxidant employed is MnO 2 and azeotropic conditions are employed, most preferably employing toluene as solvent, with a mole ratio of MnO 2 to dihydropyrimidine of from about 2 : 1 to 4 : 1 being especially preferred.
• Step a) of the process according to the first aspect of present invention forms a third aspect of the present invention.
• Step b) of the process according to the first aspect of present invention forms a fourth aspect of the present invention.
• the compounds of Formulae (1 ) or (2) may be reacted with reagents to introduce a substituent onto the exocyclic nitrogen, especially to introduce an alkyl, especially a methyl, or an alkyl- or arylsulfonyl, especially a mesyl, substituent.
• R 1 , R 2 ; E, X 1 and X 2 are as previously described;
• R 6 represents alky or aryl, preferably methyl
• R 7 is H, alkyl or aryl
• X 4 represents a leaving group, preferably CI or Br.
• Alkyl and aryl groups which may be represented by R 7 are as described above for
• R 3 represents H or a methyl group.
• R 1 , R 2 ; E, X 1 and X 2 are as previously described.
• Example 1 Preparation of Methyl 2-amino-4-(4-fluorophenyl)-6-isopropyl- pyrimidine-5-carboxylate a) A 100 ml two neck round bottom flask equipped with a condenser and connected to a nitrogen line was charged with p-fluorobenzaldehyde (0.57ml, 5mmol), methyl isobutyrylacetate ("MIBA", 0.79g, 5.5mmol), guanidine hydrochloride (1.19g, 12.5mmol), potassium carbonate (2.76g, 40mmol) and 10 ml of anhydrous dimethylformamide (DMF). This mixture was stirred and heated at 70°C for 20h.
• MIBA methyl isobutyrylacetate
• MIBA methyl isobutyrylacetate
• guanidine hydrochloride (1.19g, 12.5mmol
• potassium carbonate 2.76g, 40mmol
• Guanidine hydrochloride (24.1g), 4-Fluorobenzaldehyde (13.9g), ethyl 4-methyl-3-oxo- pentanoate (16.2g) and DMF (300ml) were charged to a vessel equipped with a condenser and connected to a nitrogen line. The resultant mixture was stirred until a clear solution was obtained. Sodium carbonate (26.8g) was charged and the mixture heated to 70°C for 4 hours. The reaction mixture contained ethyl 2-amino-4-(4-fluorophenyl)-6- isopropyl-1 ,6-dihydropyrimidine-5-carboxylate in 75% yield.
• Methyl 4-methyl-3-oxo-pentanoate (304g), isopropyl alcohol (500ml) and p-toluenesulfonic acid (3.8g) were stirred together and heated to reflux at 90°C. After 3 hours, 400ml of solvent was collected by distillation at atmospheric pressure. Fresh isopropyl alcohol was added and the mixture refluxed for a further 3 hours. The cycle of distillation, addition of fresh solvent and refluxing was continued until the conversion had reached 95%, determined by a peak area ratio of product : starting material of 95 : 5 measured by LC.
• Guanidine hydrochloride (12.1g), 4-Fluorobenzaldehyde (7.0g), isopropyl 4-methyl-3-oxo- pentanoate (8.9g) and DMF (150ml) were charged to a vessel equipped with a condenser and connected to a nitrogen line. The resultant mixture was stirred until a clear solution was obtained. Potassium carbonate (17.5g) was charged and the mixture heated to 70°C for 3 hours. The reaction mixture was cooled to ambient temperature, filtered, and the solvents removed by evaporation under reduced pressure.
• Example 6 Preparation of Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methylamino-1,6- dihydropyrimidine-5-carboxylate
• 1-Methylguanidine hydrochloride (8.25g), 4-Fluorobenzaldehyde (4.2g), ethyl 4-methyl-3- oxo-pentanoate (5.0g) and DMF (100ml) were charged to a vessel equipped with a condenser and connected to a nitrogen line. The resultant mixture stirred until a clear solution is obtained. Sodium carbonate (4.0g) was charged and the mixture heated to 70°C for 2 hours.
• reaction mixture was cooled to ambient temperature, filtered, and the solvents removed by evaporation under reduced pressure.
• the resultant oil was triturated in water at 50°C and cooled to give a slurry that was filtered and dried to give ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methylamino-1 ,6-dihydropyrimidine-5-carboxylate in 63% yield.
• Ethyl 2-amino-4-(4-fluorophenyl)-6-isopropyl-1 ,6-dihydropyrimidine-5-carboxylate (22.6g) was dissolved in toluene (150ml) and heated until a solution was obtained.
• Manganese dioxide (18.8g) was added as a slurry in toluene (150ml) and the mixture refluxed under azeotropic conditions for 6 hours until conversion was complete. A small amount of water was collected in the Dean and Stark trap.
• Example 9 The process of Example 9 was repeated, but using elemental sulfur (4.7g) in place of the manganese dioxide, and a reaction time of 24 hours. The product was obtained in a near quantitative conversion.
• Example 9 The process of Example 9 was repeated but employing 10mmol of ethyl 4-(4- fluorophenyl)-6-isopropyl-2-methylamino-1 ,6-dihydropyhmidine-5-carboxylate in place of ethyl 2-amino-4-(4-fluorophenyl)-6-isopropyl-1 ,6-dihydropyrimidine-5-carboxylate, with the other reagents and components reduced proportionately. The product was obtained in a near quantitative conversion.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Plural Heterocyclic Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Catalysts (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Indole Compounds (AREA)

Priority Applications (19)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (3)

Family

ID=32600665

Family Applications (1)

Country Status (22)

Cited By (10)

Families Citing this family (7)

Citations (2)

Family Cites Families (37)

• 2003
  • 2003-12-09 JP JP2005502458A patent/JP4579821B2/ja not_active Expired - Fee Related
  • 2003-12-09 US US10/537,723 patent/US7524955B2/en not_active Expired - Fee Related
  • 2003-12-09 SI SI200331722T patent/SI1578731T1/sl unknown
  • 2003-12-09 PT PT03780362T patent/PT1578731E/pt unknown
  • 2003-12-09 DE DE60330050T patent/DE60330050D1/de not_active Expired - Lifetime
  • 2003-12-09 EP EP03780362A patent/EP1578731B1/en not_active Expired - Lifetime
  • 2003-12-09 MX MXPA05006425A patent/MXPA05006425A/es active IP Right Grant
  • 2003-12-09 ES ES03780362T patent/ES2335279T3/es not_active Expired - Lifetime
  • 2003-12-09 AT AT03780362T patent/ATE448209T1/de active
  • 2003-12-09 DK DK03780362.4T patent/DK1578731T3/da active
  • 2003-12-09 KR KR1020057010964A patent/KR101060215B1/ko not_active Expired - Fee Related
  • 2003-12-09 EP EP09159247A patent/EP2088142A3/en not_active Ceased
  • 2003-12-09 CA CA2509344A patent/CA2509344C/en not_active Expired - Fee Related
  • 2003-12-09 BR BR0317313-5A patent/BR0317313A/pt not_active IP Right Cessation
  • 2003-12-09 AU AU2003288443A patent/AU2003288443B2/en not_active Ceased
  • 2003-12-09 WO PCT/GB2003/005359 patent/WO2004054986A2/en not_active Ceased
  • 2003-12-09 NZ NZ540722A patent/NZ540722A/en not_active IP Right Cessation
  • 2003-12-10 AR ARP030104541A patent/AR042355A1/es unknown
  • 2003-12-12 MY MYPI20034768A patent/MY138051A/en unknown
  • 2003-12-16 TW TW092135557A patent/TWI322145B/zh not_active IP Right Cessation
• 2005
  • 2005-05-30 IL IL168884A patent/IL168884A/en not_active IP Right Cessation
  • 2005-06-08 NO NO20052781A patent/NO330983B1/no not_active IP Right Cessation
• 2009
  • 2009-03-16 US US12/404,575 patent/US8273878B2/en not_active Expired - Fee Related
• 2010
  • 2010-01-11 CY CY20101100025T patent/CY1110605T1/el unknown
  • 2010-06-23 JP JP2010142779A patent/JP5318037B2/ja not_active Expired - Fee Related
• 2011
  • 2011-03-10 NO NO20110366A patent/NO20110366L/no not_active Application Discontinuation

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events